Cargando…

Lung involvement in macrophage activation syndrome and severe COVID-19: results from a cross-sectional study to assess clinical, laboratory and artificial intelligence–radiological differences

OBJECTIVES: To evaluate the clinical pictures, laboratory tests and imaging of patients with lung involvement, either from severe COVID-19 or macrophage activation syndrome (MAS), in order to assess how similar these two diseases are. METHODS: The present work has been designed as a cross-sectional...

Descripción completa

Detalles Bibliográficos
Autores principales: Ruscitti, Piero, Bruno, Federico, Berardicurti, Onorina, Acanfora, Chiara, Pavlych, Viktoriya, Palumbo, Pierpaolo, Conforti, Alessandro, Carubbi, Francesco, Di Cola, Ilenia, Di Benedetto, Paola, Cipriani, Paola, Grassi, Davide, Masciocchi, Carlo, Iagnocco, Annamaria, Barile, Antonio, Giacomelli, Roberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7456556/
https://www.ncbi.nlm.nih.gov/pubmed/32719039
http://dx.doi.org/10.1136/annrheumdis-2020-218048
_version_ 1783575820068978688
author Ruscitti, Piero
Bruno, Federico
Berardicurti, Onorina
Acanfora, Chiara
Pavlych, Viktoriya
Palumbo, Pierpaolo
Conforti, Alessandro
Carubbi, Francesco
Di Cola, Ilenia
Di Benedetto, Paola
Cipriani, Paola
Grassi, Davide
Masciocchi, Carlo
Iagnocco, Annamaria
Barile, Antonio
Giacomelli, Roberto
author_facet Ruscitti, Piero
Bruno, Federico
Berardicurti, Onorina
Acanfora, Chiara
Pavlych, Viktoriya
Palumbo, Pierpaolo
Conforti, Alessandro
Carubbi, Francesco
Di Cola, Ilenia
Di Benedetto, Paola
Cipriani, Paola
Grassi, Davide
Masciocchi, Carlo
Iagnocco, Annamaria
Barile, Antonio
Giacomelli, Roberto
author_sort Ruscitti, Piero
collection PubMed
description OBJECTIVES: To evaluate the clinical pictures, laboratory tests and imaging of patients with lung involvement, either from severe COVID-19 or macrophage activation syndrome (MAS), in order to assess how similar these two diseases are. METHODS: The present work has been designed as a cross-sectional single-centre study to compare characteristics of patients with lung involvement either from MAS or severe COVID-19. Chest CT scans were assessed by using an artificial intelligence (AI)-based software. RESULTS: Ten patients with MAS and 47 patients with severe COVID-19 with lung involvement were assessed. Although all patients showed fever and dyspnoea, patients with MAS were characterised by thrombocytopaenia, whereas patients with severe COVID-19 were characterised by lymphopaenia and neutrophilia. Higher values of H-score characterised patients with MAS when compared with severe COVID-19. AI-reconstructed images of chest CT scan showed that apical, basal, peripheral and bilateral distributions of ground-glass opacities (GGOs), as well as apical consolidations, were more represented in severe COVID-19 than in MAS. C reactive protein directly correlated with GGOs extension in both diseases. Furthermore, lymphopaenia inversely correlated with GGOs extension in severe COVID-19. CONCLUSIONS: Our data could suggest laboratory and radiological differences between MAS and severe COVID-19, paving the way for further hypotheses to be investigated in future confirmatory studies.
format Online
Article
Text
id pubmed-7456556
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-74565562020-09-04 Lung involvement in macrophage activation syndrome and severe COVID-19: results from a cross-sectional study to assess clinical, laboratory and artificial intelligence–radiological differences Ruscitti, Piero Bruno, Federico Berardicurti, Onorina Acanfora, Chiara Pavlych, Viktoriya Palumbo, Pierpaolo Conforti, Alessandro Carubbi, Francesco Di Cola, Ilenia Di Benedetto, Paola Cipriani, Paola Grassi, Davide Masciocchi, Carlo Iagnocco, Annamaria Barile, Antonio Giacomelli, Roberto Ann Rheum Dis Epidemiology OBJECTIVES: To evaluate the clinical pictures, laboratory tests and imaging of patients with lung involvement, either from severe COVID-19 or macrophage activation syndrome (MAS), in order to assess how similar these two diseases are. METHODS: The present work has been designed as a cross-sectional single-centre study to compare characteristics of patients with lung involvement either from MAS or severe COVID-19. Chest CT scans were assessed by using an artificial intelligence (AI)-based software. RESULTS: Ten patients with MAS and 47 patients with severe COVID-19 with lung involvement were assessed. Although all patients showed fever and dyspnoea, patients with MAS were characterised by thrombocytopaenia, whereas patients with severe COVID-19 were characterised by lymphopaenia and neutrophilia. Higher values of H-score characterised patients with MAS when compared with severe COVID-19. AI-reconstructed images of chest CT scan showed that apical, basal, peripheral and bilateral distributions of ground-glass opacities (GGOs), as well as apical consolidations, were more represented in severe COVID-19 than in MAS. C reactive protein directly correlated with GGOs extension in both diseases. Furthermore, lymphopaenia inversely correlated with GGOs extension in severe COVID-19. CONCLUSIONS: Our data could suggest laboratory and radiological differences between MAS and severe COVID-19, paving the way for further hypotheses to be investigated in future confirmatory studies. BMJ Publishing Group 2020-09 2020-07-21 /pmc/articles/PMC7456556/ /pubmed/32719039 http://dx.doi.org/10.1136/annrheumdis-2020-218048 Text en © Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ. This article is made freely available for use in accordance with BMJ’s website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.https://bmj.com/coronavirus/usage
spellingShingle Epidemiology
Ruscitti, Piero
Bruno, Federico
Berardicurti, Onorina
Acanfora, Chiara
Pavlych, Viktoriya
Palumbo, Pierpaolo
Conforti, Alessandro
Carubbi, Francesco
Di Cola, Ilenia
Di Benedetto, Paola
Cipriani, Paola
Grassi, Davide
Masciocchi, Carlo
Iagnocco, Annamaria
Barile, Antonio
Giacomelli, Roberto
Lung involvement in macrophage activation syndrome and severe COVID-19: results from a cross-sectional study to assess clinical, laboratory and artificial intelligence–radiological differences
title Lung involvement in macrophage activation syndrome and severe COVID-19: results from a cross-sectional study to assess clinical, laboratory and artificial intelligence–radiological differences
title_full Lung involvement in macrophage activation syndrome and severe COVID-19: results from a cross-sectional study to assess clinical, laboratory and artificial intelligence–radiological differences
title_fullStr Lung involvement in macrophage activation syndrome and severe COVID-19: results from a cross-sectional study to assess clinical, laboratory and artificial intelligence–radiological differences
title_full_unstemmed Lung involvement in macrophage activation syndrome and severe COVID-19: results from a cross-sectional study to assess clinical, laboratory and artificial intelligence–radiological differences
title_short Lung involvement in macrophage activation syndrome and severe COVID-19: results from a cross-sectional study to assess clinical, laboratory and artificial intelligence–radiological differences
title_sort lung involvement in macrophage activation syndrome and severe covid-19: results from a cross-sectional study to assess clinical, laboratory and artificial intelligence–radiological differences
topic Epidemiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7456556/
https://www.ncbi.nlm.nih.gov/pubmed/32719039
http://dx.doi.org/10.1136/annrheumdis-2020-218048
work_keys_str_mv AT ruscittipiero lunginvolvementinmacrophageactivationsyndromeandseverecovid19resultsfromacrosssectionalstudytoassessclinicallaboratoryandartificialintelligenceradiologicaldifferences
AT brunofederico lunginvolvementinmacrophageactivationsyndromeandseverecovid19resultsfromacrosssectionalstudytoassessclinicallaboratoryandartificialintelligenceradiologicaldifferences
AT berardicurtionorina lunginvolvementinmacrophageactivationsyndromeandseverecovid19resultsfromacrosssectionalstudytoassessclinicallaboratoryandartificialintelligenceradiologicaldifferences
AT acanforachiara lunginvolvementinmacrophageactivationsyndromeandseverecovid19resultsfromacrosssectionalstudytoassessclinicallaboratoryandartificialintelligenceradiologicaldifferences
AT pavlychviktoriya lunginvolvementinmacrophageactivationsyndromeandseverecovid19resultsfromacrosssectionalstudytoassessclinicallaboratoryandartificialintelligenceradiologicaldifferences
AT palumbopierpaolo lunginvolvementinmacrophageactivationsyndromeandseverecovid19resultsfromacrosssectionalstudytoassessclinicallaboratoryandartificialintelligenceradiologicaldifferences
AT confortialessandro lunginvolvementinmacrophageactivationsyndromeandseverecovid19resultsfromacrosssectionalstudytoassessclinicallaboratoryandartificialintelligenceradiologicaldifferences
AT carubbifrancesco lunginvolvementinmacrophageactivationsyndromeandseverecovid19resultsfromacrosssectionalstudytoassessclinicallaboratoryandartificialintelligenceradiologicaldifferences
AT dicolailenia lunginvolvementinmacrophageactivationsyndromeandseverecovid19resultsfromacrosssectionalstudytoassessclinicallaboratoryandartificialintelligenceradiologicaldifferences
AT dibenedettopaola lunginvolvementinmacrophageactivationsyndromeandseverecovid19resultsfromacrosssectionalstudytoassessclinicallaboratoryandartificialintelligenceradiologicaldifferences
AT ciprianipaola lunginvolvementinmacrophageactivationsyndromeandseverecovid19resultsfromacrosssectionalstudytoassessclinicallaboratoryandartificialintelligenceradiologicaldifferences
AT grassidavide lunginvolvementinmacrophageactivationsyndromeandseverecovid19resultsfromacrosssectionalstudytoassessclinicallaboratoryandartificialintelligenceradiologicaldifferences
AT masciocchicarlo lunginvolvementinmacrophageactivationsyndromeandseverecovid19resultsfromacrosssectionalstudytoassessclinicallaboratoryandartificialintelligenceradiologicaldifferences
AT iagnoccoannamaria lunginvolvementinmacrophageactivationsyndromeandseverecovid19resultsfromacrosssectionalstudytoassessclinicallaboratoryandartificialintelligenceradiologicaldifferences
AT barileantonio lunginvolvementinmacrophageactivationsyndromeandseverecovid19resultsfromacrosssectionalstudytoassessclinicallaboratoryandartificialintelligenceradiologicaldifferences
AT giacomelliroberto lunginvolvementinmacrophageactivationsyndromeandseverecovid19resultsfromacrosssectionalstudytoassessclinicallaboratoryandartificialintelligenceradiologicaldifferences